Skip to Content
주식/증권 📉 부정적

Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

요약

The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.